Abstract
Antiretroviral therapy (ART) has significantly reduced the morbidity and mortality of patients infected with the human immunodeficiency virus 1 (HIV-1). In a significant number of patients, ART is associated with fat redistribution and metabolic alterations such as dyslipidemia, insulin resistance (IR) and type 2 diabetes, summarized under the term HIV-associated lipodystrophy syndrome (HIVLS). The pathogenesis of HIV-LS is complex and involves a number of factors including ART, HIV-1, abnormal fat redistribution, metabolic abnormalities and chronic inflammation. In view of a novel understanding on how chronic inflammation contributes to the pathogenesis of HIV-1 infection, this review focuses on the interaction of the immune system and metabolic pathways and the potential consequences for the HIV-LS. Based on the current literature, we suggest a central role of systemic inflammation in triggering and deteriorating various components of the HIV-LS.
Keywords: Antiretroviral therapy, HIV-1, fat redistribution, metabolic syndrome, chronic inflammation
Current Pharmaceutical Design
Title: Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients
Volume: 16 Issue: 30
Author(s): Metodi V. Stankov and Georg M.N. Behrens
Affiliation:
Keywords: Antiretroviral therapy, HIV-1, fat redistribution, metabolic syndrome, chronic inflammation
Abstract: Antiretroviral therapy (ART) has significantly reduced the morbidity and mortality of patients infected with the human immunodeficiency virus 1 (HIV-1). In a significant number of patients, ART is associated with fat redistribution and metabolic alterations such as dyslipidemia, insulin resistance (IR) and type 2 diabetes, summarized under the term HIV-associated lipodystrophy syndrome (HIVLS). The pathogenesis of HIV-LS is complex and involves a number of factors including ART, HIV-1, abnormal fat redistribution, metabolic abnormalities and chronic inflammation. In view of a novel understanding on how chronic inflammation contributes to the pathogenesis of HIV-1 infection, this review focuses on the interaction of the immune system and metabolic pathways and the potential consequences for the HIV-LS. Based on the current literature, we suggest a central role of systemic inflammation in triggering and deteriorating various components of the HIV-LS.
Export Options
About this article
Cite this article as:
V. Stankov Metodi and M.N. Behrens Georg, Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients, Current Pharmaceutical Design 2010; 16 (30) . https://dx.doi.org/10.2174/138161210793563473
DOI https://dx.doi.org/10.2174/138161210793563473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics Meet Our Editorial Board Member
Current Radiopharmaceuticals Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology An Artificial Neural Network Model for Predicting the Subcellular Localization of Photosensitisers for Photodynamic Therapy of Solid Tumours
Current Medicinal Chemistry Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Neural Stem Cells - A Promising Potential Therapy for Brain Tumors
Current Stem Cell Research & Therapy Editorial
Current Radiopharmaceuticals The Plasma Levels of hsa-miR-19b-3p, hsa-miR-125b-5p, and hsamiR- 320c in Patients with Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS)
MicroRNA Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Subject Index To Volune 2
Current Cancer Therapy Reviews Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design